Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 64Neoplasm Metastasis 25Kidney Neoplasms 21Neoplasms 16Breast Neoplasms 15Carcinoma, Non-Small-Cell Lung 13Urinary Bladder Neoplasms 12Prostatic Neoplasms 10Lung Neoplasms 8Brain Neoplasms 8Melanoma 7Colorectal Neoplasms 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Neuroendocrine Tumors 6Liver Neoplasms 6Glioblastoma 6Gastrointestinal Stromal Tumors 6Carcinoma, Hepatocellular 6Thyroid Neoplasms 5Thymoma 5Small Cell Lung Carcinoma 5Recurrence 5Multiple Myeloma 5Esophageal Neoplasms 5Carcinoma 5Uveal Melanoma 4Stomach Neoplasms 4Sarcoma 4Adenocarcinoma 4

Interventions

Oxaliplatin 5Capecitabine 5Paclitaxel 4apatinib 3Fluorouracil 3Docetaxel 3Cisplatin 3S 1 (combination) 2Leucovorin 2titanium silicide 1rucaparib 1relatlimab 1raltitrexed 1pazopanib 1olaparib 1linrodostat 1endostar protein 1durvalumab 1dacomitinib 1capivasertib 1camrelizumab 1Sunitinib 1SHR-1701 1Nivolumab 1Ipilimumab 1HMPL-013 1Epirubicin 1Doxorubicin 1CF regimen 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Gastric Cancer × Sunitinib × Clear all
NCT01238055 2013-04-09

Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer

Samsung Medical Center

Phase 2 Completed
116 enrolled
Gastrointestinal

Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡